Crawford lands on his feet
Former FDA Commissioner Lester Crawford joins the Washington, D.C.-based lobbying firm Policy Directions as senior counsel. The firm has served the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and several major pharmaceutical companies. According to public disclosures, PhRMA paid Policy Directions $120,000 in 2005 to lobby Congress, HHS and FDA on pharmaceutical importation, FDA regulation and user fees. Additionally, Merck and Genzyme each paid the firm $80,000 in 2005. According to Policy Direction's website, the firm was involved in modifying the Controlled Substances Act, helped garner support for the "Best Pharmaceuticals for Children Act" and "successfully achieved FDA advisory committee support for a product that had originally been voted down." Crawford's abrupt departure from FDA in September is currently under review by the HHS Inspector General (1"The Pink Sheet" Sept. 26, 2005, p. 3)...
You may also be interested in...
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.